Form 13-F position report

ATTOVIA THERAPEUTIS INC COM

Reported by EcoR1 Capital LLC

ATTO CUSIP 04987L102 Manager CIK 0001587114

First reported at 2,024,010 shares this quarter.

New
% of reported 13F value 1.54% This manager · Q3 2026
Shares 2,024,010 Quarter-end amount reported
Reported value $34,691,531 Fair value at quarter end
Consecutive quarters held 1 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2026-09-30 34691531

Quarterly position history

How this manager's reported quarter-end position changed over time.

1 quarter
Quarterly reported position history for ATTOVIA THERAPEUTIS INC COM held by EcoR1 Capital LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 New 2,024,010 +2,024,010 (0.0%) 1.54% $34,691,531 2026-11-16

Who else reported the position

64 managers reported ATTOVIA THERAPEUTIS INC COM for Q3 2026.

Managers reporting ATTOVIA THERAPEUTIS INC COM in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Frazier Life Sciences Management L P New 7,046,271 +7,046,271 3.0% $120,773,085 1 qtr
The Goldman Sachs Group Inc New 5,391,772 +5,391,772 < 0.01% $92,414,972 1 qtr
venBio Partners LLC New 4,181,366 +4,181,366 14.45% $71,668,613 1 qtr
Deep Track Capital LP New 3,207,138 +3,207,138 0.9% $54,970,345 1 qtr
EcoR1 Capital LLC This report New 2,024,010 +2,024,010 1.54% $34,691,531 1 qtr
Nextech Invest Ltd New 1,835,139 +1,835,139 1.41% $31,454,282 1 qtr
Cormorant Asset Management LP New 1,788,815 +1,788,815 2.06% $30,660,285 1 qtr
Redmile Group LLC New 1,163,587 +1,163,587 1.46% $19,943,881 1 qtr
COMMODORE CAPITAL LP New 1,160,000 +1,160,000 1.54% $19,882,400 1 qtr
Sanofi New 1,082,855 +1,082,855 2.95% $18,560,135 1 qtr
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
COM ADDED

Voting authority reported

Sole
2,024,010
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.